Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
AVG Technologies NV (NYSE: AVG) shares spiked 13.23 percent to close at $19.60 a share Thursday. The stock traded between $17.96 and $21.02 on volume of 4.16 million shares traded. The company reported a GAAP net income of $12.8 million for the fourth quarter of 2013, compared to $4.9 million a year ago. Shares of AVG Technologies are up approximately 13.0 percent year-to-date.
Get more information on AVG Technologies and free access to the in-depth equity report at: www.FiveStarEquities.com/AVG
Microvision, Inc. (NASDAQ: MVIS) shares skyrocketed 97.78 percent to close at $2.67 a share Thursday. The stock traded between $1.48 and $3.18 on volume 32.56 million shares traded. Sony has announced that it is developing a new pico projector module that incorporates MicroVision's PicoP technology. Shares of Microvision are up approximately 100.0 percent year-to-date.
Get more information on Microvision free access to the in-depth equity report at: www.FiveStarEquities.com/MVIS
Onconova Therapeutics Inc. (NASDAQ: ONTX) shares plunged 36.58 percent to close at $8.79 a share Thursday. The stock traded between $7.75 and $8.87 on volume of 3.35 million shares traded. The company announced that rigosertib did not meet the primary endpoint in the recent Phase 3 ONTIME Trial. Shares of Onconova Therapeutics are down approximately 23.0 percent year-to-date.
Get more information on Onconova Therapeutics and free access to the in-depth equity report at: www.FiveStarEquities.com/ONTX
Raptor Pharmaceutical Corp. (NASDAQ: RPTP) shares surged 14.88 percent to close at $17.14 a share Thursday. The stock traded between $16.33 and $17.72 on volume 8.15 million shares traded. The company announced RP103, a potential treatment for Huntington's Disease, met its primary endpoint in recent Phase 2/3 clinical trial. Shares of Raptor Pharmaceutical are up approximately 30.0 percent year-to-date.
Get more information on Raptor Pharmaceutical and free access to the in-depth equity report at: www.FiveStarEquities.com/RPTP
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact: Five Star Equities [email protected]